Summary
Updated Aug 31, 2026
Abizer Gaslightwala is CEO, Director of Akari Therapeutics Plc (AKTX). 5 SEC Form 4 filings on record going back to 2024, most recently on 26 June 2026. Most recent open-market trade: bought $3K of AKTX on 29 August 2025. Lifetime open-market purchases: $457K. Historical track record: 3/5 stars across 5 tracked purchases.
Recent Transactions
5Every recent SEC Form 4 transaction Abizer Gaslightwala has reported, most recent first.
Track Record
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★☆☆ (3/5) |
| Total purchases tracked | 5 |
| Purchases with forward-return data | 5 |
| 30-day win rate | 60% |
| 90-day win rate | 0% |
| Avg 5-day return | -6.04% |
| Avg 30-day return | +2.73% |
| Avg 90-day return | -36.54% |
| Best 30-day return | +25.42% |
Trading Pattern
InsiderAlpha's records for Abizer Gaslightwala go back to 2024: 5 primary Form 4 filings, an average of 1.7 per year. The typical open-market purchase is $65K (7 buys totaling $457K). The largest single buy on record is $312K of AKTX in 2025. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Abizer Gaslightwala files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Hoyoung Huh - $1.50M of AKTX open-market activity in the last 12 months
- Raymond Prudo-Chlebosz - $406K of AKTX open-market activity in the last 12 months
- Samir Rashmikant Patel - $344K of AKTX open-market activity in the last 12 months
- Sandip I. Patel - $162K of AKTX open-market activity in the last 12 months
- Robert B. Bazemore - $62K of AKTX open-market activity in the last 12 months
- Kameel D. Farag - $10K of AKTX open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Abizer Gaslightwala?
Abizer Gaslightwala is a corporate insider, tracked as CEO, Director of Akari Therapeutics Plc (AKTX). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Abizer Gaslightwala submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Abizer Gaslightwala been buying or selling stock?
Recorded transactions: 7 open-market purchases ($457K) and 0 open-market sales across all tracked filings.
How accurate is Abizer Gaslightwala's historical track record?
Across 5 tracked purchases, Abizer Gaslightwala averaged +2.7% avg 30-day return with a 60% 30-day win rate. InsiderAlpha rates the track record at 3/5 stars.
Where can I see all of Abizer Gaslightwala's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Abizer Gaslightwala and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial